CANCER TEST
CARCINOMA OF UNKNOWN PRIMARY (CUP)

LI.B.E.R.O. & LI.B.E.R.O. PLUS (liquid biopsy)

Information

Ερωτήσεις

Turn Around Time:

LI.B.E.R.O. (liquid biopsy): 2 weeks*

LI.B.E.R.O. PLUS (liquid biopsy): 2 weeks*

* In case additional enrichment of the material is required, for the successful results of the tests, we will contact you.

ΘΕΛΩ ΤO TEST

I Choose liquid biopsy

LI.B.E.R.O.

LI.B.E.R.O. is an innovative, non-invasive liquid biopsy test performed on blood, the purpose of which is to select the optimal treatment and concerns patients diagnosed with cancer.

LI.B.E.R.O. provides the necessary information overcoming the need to take a new biopsy, which is often impossible (tumor accessibility, tumor heterogeneity).

The sample is taken with a routine blood draw.

LI.B.E.R.O. has the ability to detect DNA/RNA from tumor cells circulating in the blood (ctDNA/RNA). LI.B.E.R.O. detects clinically useful gene alterations, including point mutations (SNVs), insertions and deletions (INDELs), copy number variants (CNAs) and rearrangements (fusions), which cause cancer or are associated with response to treatment. A total of 80 genes are tested .

LI.B.E.R.O. also tests for microsatellite instability (MSI) , a predictive biomarker for immunotherapy treatment.

LI.B.E.R.O. PLUS

LI.B.E.R.O. PLUS tests 222 genes , microsatellite instability (MSI) , as well as Tumor Mutational Burden (TMB) , providing an even more detailed and broad molecular profile of the cancer.

Στην Μικροδιαγνωστική, από την παραλαβή του δείγματος, την θέσπιση διάγνωσης μέχρι και την ολοκλήρωση του μοριακού προφίλ ενός ασθενή, η διαδικασία διέπεται από τις αρχές της διασφάλισης της Ποιότητας στην διεξαγωγή όλων των επιμέρους εξετάσεων.

When can LI.B.E.R.O. & LI.B.E.R.O. PLUS liquid biopsy be applied?

-When the patient cannot support a repeat biopsy
-When the tumor is inaccessible
-When the available tissue is minimal or exhausted (paraffin cube)
-When a repeat biopsy is not recommended
-When the patient does not respond to treatment and there is a need for reassessment

What is the clinical utility of LI.B.E.R.O. & LI.B.E.R.O. PLUS liquid biopsy?

-Guides treatment selection for primary and metastatic disease
-Reassesses treatment for resistance to the applied treatment regimen
-Provides FDA/EMA approved treatment options
-Identifies potential mutations that may arise in distant unresectable metastatic lesions
-Detects tumor heterogeneity
-Provides a comprehensive genomic profile of the tumor
-Provides rapid results, ensuring that treatment can begin sooner.

How is LI.B.E.R.O. & LI.B.E.R.O. PLUS liquid biopsy performed & what sample is required?

A small amount of blood (~20 ml) is taken, as in a routine hematology test. In case the blood collection is not done at Microdiagnostics facilities, the blood should be collected in 10ml Streck vials (please contact us to supply them to you).

Transport conditions: The blood vials are kept at room temperature. Please note that the blood should not be refrigerated, exposed to ice packs, or frozen. After collection, it is recommended that it be transported at Microdiagnostics facilities as soon as possible.

Frequently Asked Questions (FAQ)

How will LI.B.E.R.O. & LI.B.E.R.O. PLUS liquid biopsy help me?

LI.B.E.R.O. & LI.B.E.R.O. PLUS guides the appropriate treatment choice for primary and metastatic forms of the disease, reassesses the efficacy of the existing treatment regimen in case of resistance development and suggests therapies approved by the FDA and EMA. At the same time, it identifies potential mutations in distant, unresectable metastatic foci, captures tumor heterogeneity and offers a complete genomic profile of the tumor, while providing immediate results so that treatment can be started as soon as possible.